We are beyond excited to announce that DeepPath-LYDIA, the only CE-Marked AI-powered decision-support system in the world that can identify metastasis from multiple cancer types with a single model, has officially gone live at the UMC Utrecht (University Medical Center Utrecht - pioneers at digitalpathology), fully integrated into the Sectra PACS system! This game-changing AI technology [...]
We are thrilled to announce that our dedicated team at DeepPath has won a silver medal in the recent Kaggle competition, "Predict New Medicines with BELKA" achieving the 66th place among 1946 teams! Congratulations to our great team: Konstantinos Vougas Konstantinos Gyftodimos George Kalikakis Akis Manolis Christos Spyropoulos Nikos Niotis Thomas Papathymiopoulos The BELKA competition, [...]
We are super excited to announce that DeepPath receives CE marking for DeepPath- LYDIA. The system got regulatory clearance as decision support as per IVDD for helping histopathologists detect metastases on Hematoxylin & Eosin stained lymph nodes from patients with breast cancer, colon cancer, lung cancer, and melanoma. We must note that to the best [...]
We are happy to announce that DeepPath as part of a consortium consisting of MIDA Biotech B.V. (an Orgenesis Inc. company), Leiden University, and MIRCOD LLC, acquired a €4m Pathfinder grant from European Innovation Council and SMEs Executive Agency (EISMEA) for the development of an Ai-powered platform to democratize autologous IPCS manufacturing! This is a great [...]
